|  |  | 

India Top Headlines

Covid-19: The government will soon issue guidelines on the treatment of AEFI | India News

img-responsive

NEW DELHI: The government is expected to soon issue Post Immunization Adverse Event (AEFI) guidelines that will help clinicians and Covid-19 vaccine recipients identify and treat unusual signs and symptoms in cases of ‘severe and severe ‘as rare cases. blood clots.
Some of these events were reported in countries after the administration of the AstraZeneca-Oxford University Covid-19 vaccine. Guidelines are being prepared.
The guidelines are being prepared even as a review of ‘severe and severe’ AEFIs in India indicates possible “genetic” connections in the events reported in European countries, official sources said.
In India, the national AEFI committee, which includes doctors, researchers and vaccine experts, is re-examining 700 ‘severe and severe’ AEFIs reported after people received Covid-19 injections. The results of the study will inform the guidelines that may come out this week.
AIIMS Director Dr Randeep Guleria said the incidence of thrombocytopenia (low platelet count) after vaccination is likely to be lower in India. Vaccine-related side effects are more common in Western countries compared to India or Asian countries. He also suggested that thrombocytopenia seen after vaccination was similar to heparin-induced thrombocytopenia, which is a common occurrence, and therefore treatment guidelines will not be difficult to frame.
The guidelines will explain critical indicators and treatment, along with the findings from the reassessment of serious adverse events in India, a senior official said. The official added that due attention was being paid to AEFIs and processes were being repeatedly reviewed from the district level onward. This is important because the guidelines can help clinicians better manage adverse events, even if they are rare, and possibly save lives. In addition, it will instill confidence among people who will then be aware of the symptoms to look for and report to the local AEFI committees or doctors, as well as to seek treatment.
“We are reviewing the data very closely and analyzing some of the unusual parameters in light of the reports from the European regulator and the WHO. However, these post-vaccination thrombocytopenia events are mainly specific to Western countries. They can be due to genetic problems, which is often a reason for side effects in vaccines, ”the official told TOI.
The official added that during the H1N1 swine flu pandemic, a higher incidence of narcolepsy, a rare sleep disorder, was seen among children who received the flu vaccine in Scandinavian countries. However, WHO research found that narcolepsy after vaccination against pandemic influenza was not a widespread global phenomenon.
“It takes a little more research and time to come up with the guidelines and the experts from the AEFI monitoring committee are working on it,” said Dr. Guleria. “The national committee will meet in two days to deliberate on the input received in such cases,” said committee member Dr. NK Arora. Authorities said there was “absolutely no cause for concern” with either of the two vaccines, Covishield and Covaxin, used in India.
Reports of blood clots have already led many countries to limit the use of the AstraZeneca vaccine to older people, as clots are mostly seen in younger people. Although the European Medicines Agency has said that the bleeding disorder is rare and that the benefits of the vaccine far outweigh its risks, many consider the risk unacceptable, mainly because the side effects can be fatal, while the incidence of severe Covid-19 infection itself is low. among young people.

Original source

covid-19-the-government-will-soon-issue-guidelines-on-the-treatment-of-aefi-india-news

ABOUT THE AUTHOR